Analyze of factors and prognosis of eyes lost to follow-up in retinal vein occlusive disease patients receiving anti-vascular endothelial growth factor therapy

作者全名："Huang, Xiaoying; Zheng, Minming; Lu, Jiatao; Wang, Xi; Zheng, Zheng"

作者地址："[Huang, Xiaoying; Zheng, Minming; Lu, Jiatao; Wang, Xi; Zheng, Zheng] Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing, Peoples R China"

通信作者："Zheng, Z (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Ophthalmol, Chongqing, Peoples R China."

来源：BMC OPHTHALMOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001003632600001

JCR分区：Q3

影响因子：1.7

年份：2023

卷号：23

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Retinal vein occlusion; Anti-vascular endothelial growth factor; Loss of follow-up; Influential factors

摘要："BackgroundPatients with macular edema (ME) secondary to retinal vein occlusion (RVO) who received at least one intravitreal injection of anti-vascular endothelial growth factor therapy (VEGF) and lost to follow-up (LTFU) for more than six months were analyzed to investigate the factors contributing to the LTFU and the prognosis.MethodThis was a retrospective, single-center study to analyze the causes and prognosis of LTFU over six months in RVO-ME patients treated with intravitreal anti-VEGF injections at our institution from January 2019 to August 2022 and to collect patients' baseline characteristics along with the number of injections before LTFU, primary disease, best corrected visual acuity (BCVA) before LTFU and after return visit, central macular thickness (CMT), months before LTFU and after LTFU, reasons for LTFU, and complications, to analyze the factors affecting visual outcome at a return visit.ResultsThis study included 125 patients with LTFU; 103 remained LTFU after six months, and 22 returned after LTFU. The common reason for LTFU was ""no improvement in vision"" (34.4%), followed by ""transport inconvenience"" (22.4%), 16 patients (12.8%) were unwilling to visit the clinic, 15 patients (12.0%) had already elected to seek treatment elsewhere, 12 patients (9.6%) were not seen in time due to the 2019-nCov epidemic, and 11 patients (8.8%) cannot do it due to financial reasons. The number of injections before LTFU was a risk factor for LTFU (P < 0.05). LogMAR at the initial visit (P < 0.001), CMT at the initial visit (P < 0.05), CMT before the LTFU (P < 0.001), and CMT after the return visit (P < 0.05) were influential factors for logMAR at the return visit.ConclusionMost RVO-ME patients were LTFU after anti-VEGF therapy. Long-term LTFU is greatly detrimental to the visual quality of patients; thus, the management of RVO-ME patients in follow-up should be considered."

基金机构：　

基金资助正文：